• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC.纳武利尤单抗联合伊匹木单抗：一种可能改写食管癌治疗指南的方案。
Signal Transduct Target Ther. 2022 May 25;7(1):169. doi: 10.1038/s41392-022-01022-x.
2
[New MAA: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma].[新的上市授权申请：一线纳武利尤单抗联合伊匹木单抗用于不可切除的恶性胸膜间皮瘤]
Bull Cancer. 2022 Jan;109(1):4-6. doi: 10.1016/j.bulcan.2021.07.010. Epub 2021 Oct 13.
3
Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia.纳武利尤单抗联合伊匹木单抗与纳武利尤单抗单药治疗对亚洲IV期黑色素瘤患者的真实世界疗效
Eur J Dermatol. 2021 Oct 1;31(5):662-664. doi: 10.1684/ejd.2021.4139.
4
[Drug Approval: Nivolumab plus ipilimumab for patients with MSI -high metastatic colorectal cancer previously treated with 5-fluorouracilchemotherapy].[药物批准：纳武利尤单抗联合伊匹木单抗用于既往接受过5-氟尿嘧啶化疗的微卫星高度不稳定转移性结直肠癌患者]
Bull Cancer. 2022 Jan;109(1):3-4. doi: 10.1016/j.bulcan.2021.08.010. Epub 2021 Oct 29.
5
Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution.单中心转移性黑色素瘤患者接受伊匹单抗和纳武利尤单抗治疗的临床获益探索性分析。
Clin Transl Oncol. 2022 Feb;24(2):319-330. doi: 10.1007/s12094-021-02692-9. Epub 2021 Aug 22.
6
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.纳武利尤单抗联合伊匹单抗治疗错配修复缺陷/微卫星高度不稳定转移性结直肠癌的持久临床获益。
J Clin Oncol. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.
7
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.纳武利尤单抗联合或不联合伊匹单抗治疗转移性肉瘤（Alliance A091401）：两项开放标签、非比较、随机、2 期临床试验。
Lancet Oncol. 2018 Mar;19(3):416-426. doi: 10.1016/S1470-2045(18)30006-8. Epub 2018 Jan 19.
8
A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA).一项多中心、开放标签的 II 期临床试验，旨在评估纳武利尤单抗和伊匹单抗二线治疗老年晚期食管鳞癌（RAMONA）的疗效。
BMC Cancer. 2019 Mar 14;19(1):231. doi: 10.1186/s12885-019-5446-2.
9
Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.尼伏鲁单抗和伊匹单抗治疗转移性葡萄膜黑色素瘤：一项单臂 II 期研究结果。
J Clin Oncol. 2021 Feb 20;39(6):599-607. doi: 10.1200/JCO.20.00605. Epub 2020 Oct 30.
10
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1.一线纳武利尤单抗联合伊匹木单抗对比化疗用于 PD-L1 肿瘤表达比例≥1%的晚期 NSCLC：CheckMate 227 研究的患者报告结局 1 部分
J Thorac Oncol. 2021 Apr;16(4):665-676. doi: 10.1016/j.jtho.2020.12.019. Epub 2021 Jan 21.

引用本文的文献

1
Clinical characteristics, treatment, and outcomes of nivolumab induced immune thrombocytopenia.纳武利尤单抗所致免疫性血小板减少症的临床特征、治疗及结局
Invest New Drugs. 2024 Oct;42(5):575-580. doi: 10.1007/s10637-024-01472-w. Epub 2024 Sep 12.
2
PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment.PD-1 和 PD-L1：免疫交响乐的建筑师和癌症治疗免疫疗法突破的推动者。
Front Immunol. 2023 Dec 1;14:1296341. doi: 10.3389/fimmu.2023.1296341. eCollection 2023.
3
Circular RNA circ-FIRRE interacts with HNRNPC to promote esophageal squamous cell carcinoma progression by stabilizing GLI2 mRNA.环状 RNA circ-FIRRE 通过与 HNRNPC 相互作用稳定 GLI2 mRNA 促进食管鳞癌细胞进展。
Cancer Sci. 2023 Sep;114(9):3608-3622. doi: 10.1111/cas.15899. Epub 2023 Jul 7.

本文引用的文献

1
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.纳武利尤单抗联合治疗晚期食管鳞癌。
N Engl J Med. 2022 Feb 3;386(5):449-462. doi: 10.1056/NEJMoa2111380.
2
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.一线纳武利尤单抗联合低剂量伊匹木单抗治疗微卫星高度不稳定/错配修复缺陷转移性结直肠癌：II期CheckMate 142研究
J Clin Oncol. 2022 Jan 10;40(2):161-170. doi: 10.1200/JCO.21.01015. Epub 2021 Oct 12.
3
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.帕博利珠单抗联合化疗与单纯化疗一线治疗晚期食管癌（KEYNOTE-590）：一项随机、安慰剂对照、III 期研究。
Lancet. 2021 Aug 28;398(10302):759-771. doi: 10.1016/S0140-6736(21)01234-4.
4
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.度伐利尤单抗联合或不联合替西木单抗与标准化疗用于转移性非小细胞肺癌一线治疗的 MYSTIC 期 3 随机临床试验。
JAMA Oncol. 2020 May 1;6(5):661-674. doi: 10.1001/jamaoncol.2020.0237.
5
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.肿瘤突变负担与纳武利尤单抗单药治疗及联合伊匹单抗治疗小细胞肺癌的疗效。
Cancer Cell. 2018 May 14;33(5):853-861.e4. doi: 10.1016/j.ccell.2018.04.001. Epub 2018 May 3.

Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC.

作者信息

Luo Yuejun, Sun Nan, He Jie

机构信息

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China.

State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

Signal Transduct Target Ther. 2022 May 25;7(1):169. doi: 10.1038/s41392-022-01022-x.

DOI:10.1038/s41392-022-01022-x
PMID:35614047
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9132968/
Abstract
摘要